FY2026 EPS Estimates for McKesson Lowered by Leerink Partnrs

McKesson Co. (NYSE:MCK - Free Report) - Leerink Partnrs lowered their FY2026 earnings estimates for McKesson in a research note issued on Tuesday, May 27th. Leerink Partnrs analyst M. Cherny now anticipates that the company will post earnings per share of $37.43 for the year, down from their prior forecast of $37.73. The consensus estimate for McKesson's current full-year earnings is $32.77 per share. Leerink Partnrs also issued estimates for McKesson's Q4 2026 earnings at $11.17 EPS, FY2027 earnings at $42.37 EPS and FY2028 earnings at $48.06 EPS.

MCK has been the subject of a number of other reports. Evercore ISI lifted their price target on shares of McKesson from $650.00 to $675.00 and gave the company an "outperform" rating in a research report on Thursday, February 6th. Wall Street Zen upgraded shares of McKesson from a "buy" rating to a "strong-buy" rating in a research report on Friday. Wells Fargo & Company lifted their price objective on McKesson from $691.00 to $766.00 and gave the stock an "equal weight" rating in a research report on Tuesday. UBS Group lifted their price objective on McKesson from $708.00 to $805.00 and gave the stock a "buy" rating in a research report on Tuesday, April 29th. Finally, Cfra Research downgraded McKesson from a "moderate buy" rating to a "hold" rating in a research report on Friday, April 4th. Three research analysts have rated the stock with a hold rating, eleven have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $692.46.

McKesson Price Performance

Shares of MCK stock traded down $8.67 during midday trading on Friday, reaching $713.08. 302,847 shares of the company traded hands, compared to its average volume of 953,788. The firm's 50 day simple moving average is $696.36 and its two-hundred day simple moving average is $638.76. McKesson has a 1-year low of $464.42 and a 1-year high of $731.00. The firm has a market cap of $89.21 billion, a PE ratio of 32.65, a price-to-earnings-growth ratio of 1.29 and a beta of 0.53.

McKesson (NYSE:MCK - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported $10.12 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $9.83 by $0.29. McKesson had a net margin of 0.82% and a negative return on equity of 181.26%. The company had revenue of $90.82 billion during the quarter, compared to the consensus estimate of $94 billion. During the same period last year, the firm earned $6.18 EPS. The company's revenue for the quarter was up 18.9% on a year-over-year basis.

McKesson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, July 1st. Shareholders of record on Monday, June 2nd will be paid a $0.71 dividend. The ex-dividend date of this dividend is Monday, June 2nd. This represents a $2.84 annualized dividend and a yield of 0.40%. McKesson's payout ratio is currently 10.99%.

Insiders Place Their Bets

In other news, EVP Thomas L. Rodgers sold 2,891 shares of the business's stock in a transaction on Friday, May 30th. The shares were sold at an average price of $712.18, for a total transaction of $2,058,912.38. Following the completion of the sale, the executive vice president now directly owns 2,544 shares of the company's stock, valued at $1,811,785.92. The trade was a 53.19% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Leann B. Smith sold 1,248 shares of the business's stock in a transaction on Thursday, May 22nd. The shares were sold at an average price of $717.30, for a total transaction of $895,190.40. Following the sale, the executive vice president now directly owns 2,621 shares of the company's stock, valued at $1,880,043.30. This represents a 32.26% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 13,747 shares of company stock valued at $9,852,587. Company insiders own 0.11% of the company's stock.

Institutional Trading of McKesson

Institutional investors have recently made changes to their positions in the stock. Cibc World Market Inc. boosted its position in McKesson by 6.3% during the 4th quarter. Cibc World Market Inc. now owns 20,252 shares of the company's stock worth $11,542,000 after purchasing an additional 1,207 shares during the period. Brentview Investment Management LLC purchased a new stake in McKesson during the 4th quarter worth $3,018,000. Ingalls & Snyder LLC boosted its position in McKesson by 8.2% during the 4th quarter. Ingalls & Snyder LLC now owns 13,824 shares of the company's stock worth $7,878,000 after purchasing an additional 1,047 shares during the period. Chicago Partners Investment Group LLC boosted its position in McKesson by 85.0% during the 4th quarter. Chicago Partners Investment Group LLC now owns 1,262 shares of the company's stock worth $745,000 after purchasing an additional 580 shares during the period. Finally, OLD National Bancorp IN boosted its position in McKesson by 7.3% during the 4th quarter. OLD National Bancorp IN now owns 8,196 shares of the company's stock worth $4,671,000 after purchasing an additional 556 shares during the period. 85.07% of the stock is owned by hedge funds and other institutional investors.

McKesson Company Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.